Juvenile Myelomonocytic Leukemia in a Child: A Case Report of Palliative Chemotherapy and Literature Review Applied to Limited Resources Centers

Table 1

Protocol of palliative chemotherapy for juvenile myelomonocytic leukemia at our center and patient’s laboratory findings during treatment.

	Week
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
6-MP
ARA-C
	6-MP (6-mercaptopurine): 10 mg/m^2/day; ARA-C (cytarabine): 10 mg/m^2/week for 3 weeks.; If 6-MP is well tolerated, and WBC still high, the doses may be increased by 20% every next phase, until a maximum of 200%
Hb (gr/dL)	8.3	6.5	6.1	7.8	10.4	10	10.8	Patient at home, no lab data									9.6
Ht (%)	21.2	18.3	17.2	24.5	32.4	29.5	30										28
WBC (/μL)	236,700	99,700	11,900	7,800	10,600	26,700	47,100										30,500
Platelet (/μL)	22,000	69,000	57,000	11,000	45,000	34,000	30,900										11,000
Chemotherapy	6-MP	6-MP ARA-C	6-MP ARA-C	6-MP ARA-C		6-MP ARA-C increase 20%	6-MP ARA-C	6-MP ARA-C		6-MP ARA-C	6-MP ARA-C	6-MP ARA-C		6-MP ARA-C	6-MP ARA-C	6-MP ARA-C	Patient died

6-MP, 6-mercaptopurine; ARA-C, cytarabine.